Research Article
Can the TLR-4-Mediated Signaling Pathway Be “A Key Inflammatory Promoter for Sporadic TAA”?
Table 4
Systemic plasma mediator’s levels “AASSP” from patients and controls.
| Systemic mediators examined | Patients () | Controls () | values* |
| IL-6 (pg/mL) | | | <0.0001 | TNF- (pg/mL) | | | <0.0001 | CRP (mg/L) | | | <0.0001 | MMP-2 (ng/mL) | | | <0.0001 | MMP-9 (ng/mL) | | | <0.0001 |
| Systemic mediators examined | Patients with high responder genotype () | Patients with other genotypes () | values* |
| IL-6 (pg/mL) | | | <0.001 | TNF- (pg/mL) | | | <0.01 | CRP (mg/L) | | | 0.01 | MMP-2 (ng/mL) | | | <0.0001 | MMP-9 (ng/mL) | | | <0.0001 |
| Systemic mediators examined | Patients with high responder genotype () | Controls with high responder genotype () | values* |
| IL-6 (pg/mL) | | | <0.0001 | TNF- (pg/mL) | | | <0.01 | CRP (mg/L) | | | <0.0001 | MMP-2 (ng/mL) | | | <0.0001 | MMP-9 (ng/mL) | | | <0.0001 |
|
|
By unpaired -test with Welch correction.
|